CUDA Yanqi Lake Meeting | Professor Liqun Zhou: Advancing the Diagnostic Frontier to Improve Survival in Chinese Prostate Cancer Patients

CUDA Yanqi Lake Meeting | Professor Liqun Zhou: Advancing the Diagnostic Frontier to Improve Survival in Chinese Prostate Cancer Patients

2025.04.25
In recent years, the incidence of prostate cancer in China has continued to rise, creating an urgent need to improve diagnostic and treatment strategies tailored to this growing patient population. At the 5th Annual CUDA Yanqi Lake Meeting (2025), hosted by the Chinese Urological Doctor Association, UroStream invited Professor Liqun Zhou, Institute of Urology, Peking University, to discuss the importance of early screening, optimized diagnostic approaches, and advances in neoadjuvant therapy. His insights point toward practical steps for enhancing the survival and quality of life of prostate cancer patients in China.
Global First, with China’s Participation! Drs. Wenyu Yang & Wenbin An Discuss the Development, Highlights, and Clinical Relevance of the First International Expert Consensus on Pediatric Chronic Phase CML

Global First, with China’s Participation! Drs. Wenyu Yang & Wenbin An Discuss the Development, Highlights, and Clinical Relevance of the First International Expert Consensus on Pediatric Chronic Phase CML

2025.04.25
The recently published “Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations” in the prestigious journal Leukemia marks a historic milestone as the first international expert consensus focused on chronic-phase chronic myeloid leukemia (CML) in children and adolescents.
From Pioneering Efforts to Global Leadership – Academician Xiaojun Huang Charts China’s Transformative Journey

From Pioneering Efforts to Global Leadership – Academician Xiaojun Huang Charts China’s Transformative Journey

2025.04.23
From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong Province, alongside the “Hua Tuo Project” MDT Forum. During the event, Academician Xiaojun Huang—Conference Chair, Director of the Hematology Branch of the CPAM , and professor at Peking University People’s Hospital—delivered a landmark keynote titled "50 Years of Hematopoietic Stem Cell Transplantation." His talk provided a comprehensive review across four dimensions: historical development, China’s contributions, advances in immunotherapy, and future perspectives. He highlighted milestone achievements and global impacts—especially the original “Beijing Protocol”—and underscored how Chinese innovations are reshaping the international transplant landscape, offering valuable insights for hematologists worldwide.
Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

2025.04.23
As one of the five initial professional guideline projects launched by the Chinese Society of Clinical Oncology (CSCO) in 2016, the CSCO Breast Cancer Guidelines (CSCO BC Guidelines) have become a cornerstone of breast cancer care in China. Since the publication of the first edition in 2017, the guidelines have undergone yearly updates, evolving in both content and format. Today, they are available in multiple versions—including Chinese and English editions, pocket guides, patient education materials, and AI-based platforms—earning broad recognition from Chinese clinicians and international oncology peers alike.
Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

2025.04.23
Since the release of the 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines, numerous high-quality studies—both domestic and international—have advanced the field of hepatocellular carcinoma (HCC), especially in diagnosis, staging, and treatment. Research reflecting China's real-world clinical settings has provided important theoretical guidance for the management of liver cancer. Building on accumulated clinical experience, the National Health Commission has organized expert teams to revise the guidelines, culminating in the publication of the 2024 edition, which introduces comprehensive updates across screening, diagnosis, and treatment.
Cancer Patients Rehabilitation Rally is Underway!

Cancer Patients Rehabilitation Rally is Underway!

2025.04.23
On April 20, 2025, the "Beyond Limits" Cancer Patients Rehabilitation Rally was officially launched across China. Organized by the Cancer Rehabilitation Society of CACA , and supported by Hengrui Pharmaceuticals, the initiative harnesses digitization and other cutting-edge technologies to enhance long-term survival rates and quality of life for cancer patients.